Business context and reporting period
Daré Bioscience, Inc. is a clinical-stage biopharmaceutical company focused on women’s health. This unaudited Form 10-Q covers the quarter and six months ended June 30, 2021. The company had no approved or commercialized products and generated no revenue.
Its later-stage programs included DARE-BV1 for bacterial vaginosis, Ovaprene for non-hormonal contraception, and Sildenafil Cream 3.6% for female sexual arousal disorder. Other programs were at Phase 1 or preclinical stages.
Financial results and liquidity
| Metric | Q2 2021 | Six months 2021 | Comparable 2020 period |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Research and development expense | $7.34 million | $13.07 million | $5.55 million Q2; $7.93 million six months |
| Total operating expenses | $9.16 million | $16.86 million | $7.13 million Q2; $11.38 million six months |
| Net loss | $9.16 million | $16.49 million | $7.12 million Q2; $11.38 million six months |
| Operating cash used | Not stated separately | $20.17 million | $10.68 million six months |
Basic and diluted loss per share was $0.18 for Q2 2021 and $0.35 for the first half, compared with $0.27 and $0.45, respectively, in 2020. The six-month 2021 net loss included a $369,887 gain from forgiveness of the company’s Paycheck Protection Program loan.
At June 30, 2021, cash and cash equivalents were $9.11 million, working capital was approximately $8.1 million, and accumulated deficit was $87.9 million. Total liabilities were $7.08 million, including $492,462 in lease liabilities and $1.0 million of contingent consideration. The PPP loan had been forgiven; no note payable remained on the balance sheet. The company reported no investing cash outflow in the first half.
Financing activities provided $24.63 million in the first half, primarily from equity sales. Common shares outstanding rose from 41.6 million at December 31, 2020 to 57.4 million at June 30, 2021. Management stated that available cash was insufficient for at least the next 12 months from issuance of the financial statements and that substantial additional capital would be needed. It identified substantial doubt about the company’s ability to continue as a going concern.
Material changes versus prior periods
- Q2 operating expenses increased $2.04 million year over year; first-half expenses rose $5.48 million. R&D drove most of the increase, reflecting the Sildenafil Cream Phase 2b trial, Ovaprene manufacturing and regulatory work, and spending on earlier-stage programs.
- First-half operating cash use increased to $20.17 million from $10.68 million. The company attributed part of the 2021 outflow to a $2.5 million increase in other receivables, including the DARE-BV1 application fee expected to be refunded.
- First-half net loss increased $5.11 million year over year despite the PPP forgiveness gain. The company continued to rely on equity financing and reported significant share issuance.
Outlook, management commentary, and risks
- DARE-BV1: The FDA accepted the NDA for filing and granted Priority Review after quarter-end; the target action date was December 7, 2021. Management said that, if approved in 2021, a U.S. launch could occur in the first half of 2022. The company had not finalized its commercialization approach and did not yet have a commercial partner or its own sales infrastructure. The $2.9 million application fee was expected to be refunded in Q3 2021.
- Ovaprene: The company entered a July 2021 agreement with NICHD for a pivotal Phase 3 study, planned to start in 2022. Daré is responsible for $5.5 million of study costs and clinical supplies; NICHD manages other study costs. Bayer’s U.S. license becomes effective only if Bayer elects to pay an additional $20 million; Bayer may terminate on 90 days’ notice.
- Sildenafil Cream: Management expected Phase 2b trial costs of approximately $15–17 million, not all payable in 2021. Enrollment had slowed at some sites amid COVID-19-related operational changes; timing of interim analysis and topline results was uncertain.
- Spending: Management expected R&D expense to increase significantly in 2021, with second-half R&D spending higher than first-half spending and potentially more than double 2020 R&D expense if programs advanced as planned. It expected 2021 general and administrative expense to rise approximately 10%–15% year over year, potentially more if DARE-BV1 commercial-readiness costs were incurred.
- Funding and dilution: After June 30 and through August 9, the company received approximately $25.4 million of net ATM proceeds and an $11.45 million initial payment under a Gates Foundation grant. The grant provides up to $48.95 million through 2026 for DARE-LARC1, subject to milestones and reporting requirements, and includes global-access and humanitarian-license obligations. Subsequent funding is not assured. Further equity issuance could dilute shareholders; management also warned that capital may not be available on acceptable terms.
- Other development: Daré reported positive topline Phase 1 results for DARE-HRT1, including delivery of the target hormones over 28 days and no serious adverse events. Management planned a DARE-VVA1 Phase 1 study in 2021.
- Key risks: The company remains pre-revenue and dependent on external capital, clinical and regulatory success, and third parties. FDA review or approval of DARE-BV1 could be delayed or result in a complete response letter; commercial arrangements and market uptake are uncertain. COVID-19 could disrupt enrollment, vendors, timelines, and financing. Ovaprene’s pivotal trial depends substantially on NICHD and its contractors. The company also faces milestone, licensing, manufacturing, reimbursement, competition, and intellectual-property risks.
No material pending legal proceeding was reported. Management stated that disclosure controls and procedures were effective as of June 30, 2021.
Important facts for investors to verify
- Whether DARE-BV1 received an FDA decision by the December 7, 2021 target date, and the implications for launch timing, costs, and partnership arrangements.
- How the post-quarter ATM proceeds and Gates Foundation payment affect cash runway relative to the stated going-concern warning and ongoing operating cash burn.
- Whether subsequent grant payments are earned, and the DARE-LARC1 program’s costs, milestones, and global-access obligations.
- Progress, enrollment, costs, and timing for the Ovaprene Phase 3 study and Sildenafil Cream Phase 2b trial, including COVID-19 or third-party disruptions.
- Further share issuance and dilution, upcoming license or acquisition milestone payments, and the status of commercialization partnerships.